LDS/Medical Tests/Ribonucleoprotein P (U1RNP) Antibody (ENA)

Ribonucleoprotein P (U1RNP) Antibody (ENA)

This test identifies an antibody to a ribonucleoprotein-extractable nuclear antigen. A negative test essentially excludes Mixed Connective Tissue Disease (MCTD) because the presence of this antibody is a requirement for the diagnosis, but by itself is not sufficient for a diagnosis.  MCTD is thought by some to be related yet separate from systemic lupus erythematosus (SLE), since there are many similar clinical and serologic features.  Over time, some patients with MCTD evolve into a clinical appearance more akin to systemic sclerosis or SLE.  MCTD is not the same as "undifferentiated" or "overlap" connective tissue disease.  Typically the antibodies to ribonucleoprotein (RNP) are detected by an immunofluorescence screening technique. Usually this is based on the reactivity of antinuclear antibodies to ribonuclease in a speckled pattern. Patterns that are distinguishable by immunofluoresence are the nucleolar and speckled. The necleolar pattern is usually associated with SLE and progressive systemic sclerosis (PSS). The speckled ANA pattern is typically associated with SLE, Sjögren's syndrome, and mixed connective tissue disease (MCTD). Detection of high levels of this antibody in the absence of other antibodies is diagnostic of MCTD in the appropriate clinical setting.

Two laboratory criteria are necessary to diagnose MCTD: (1) the presence of high titer RNP antibodies and (2) the absence of anti-DNA, anti-Sm, and anti-histone antibodies. Anti-RNP antibodies, which are commonly tested for in conjunction with anti-Sm, are present in 30 to 40% of Systemic Lupus Erythematosus (SLE) patients, but usually in low titer; however, in MCTD the presence is closer to 95% and the titer is usually high (often > 10,000). Ribonuclease can be used to distinguish anti-RNP from anti-Sm antibodies since it destroys ribonucleoprotein (RNP) but not the Smith antigen. It should be noted that anti-RNP antibodies are not specific for SLE and are not useful for establishing the diagnosis of SLE. High titers of Sm and RNP antibodies have been reported in patients with renal and central nervous system disease, although others have refuted these findings. Sm antibodies may disappear with treatment, while RNP antibodies persist.

  • Diagnosis of mixed connective tissue disease
  • As an aid in diagnosis of SLE
  • As an aid in diagnosis of other autoimmune diseases

Increased in:

  • Mixed Connective Tissue Disease (96–100% sensitivity, usually high titer)
  • Systemic Lupus Erythematosus (usually low titer).
  • Overlap connective tissue disorders
  • Scleroderma
  • Sjögren syndrome
  • Rheumatoid arthritis
  • Discoid lupus

Note: Anti-RNP is present in 2.7% of patients with positive ANA.

Negative (Non-reactive)

 

 

Immunodiffusion (ID), Enzyme Linked Immunosorbent Assay (ELISA), Immunoblotting.

Serum (SST). 

Stability

  • Ambient: 5-7 days
  • Refrigerated: 7-14 days
  • Frozen: 60 days
Anti-DNA, Antinuclear Antibody, ANA Antigen Specific Profile, Anti- Sm.
1-3 days.
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
Please log in to view content.
Create an account to get a 30-day free trial.
Login
  • Clin Dermatol. 2006;24:374. [PMID: 16966019]
  • Clin Exp Rheumatol. 1989 Sep-Oct;7 Suppl 3:S57-62 [PMID: 269116]
  • Rheum Dis Clin North Am. 2005;31:411. [PMID: 16084315]
  • Lupus. 2006;15(3):132-7. [PMID: 16634365]
  • Stone JH.  Pearls and Myths in Rheumatology.  Springer, 2009.  Chapter 15.
  • Jacobs DS and DeMott WR. Laboratory Test Handbook. 5th. Hudson, OH. Lexi-Comp, Inc (2001).